1 / 50

WELCOME

WELCOME. Promoting Responsible Business in Pharmaceuticals and Private Healthcare Sector STATE LEVEL STAKEHOLDER DIALOGUE. CUTS INTERNATIONAL – RAMAN DEVELOPMENT CONSULTANTS PVT. LTD. PRESENTATION ON KEY FINDINGS: BRCC PROJECT- GUJARAT. 11 th September, 2012. Presentation P oints.

sydney
Download Presentation

WELCOME

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. WELCOME Promoting Responsible Business in Pharmaceuticals and Private Healthcare Sector STATE LEVEL STAKEHOLDER DIALOGUE RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  2. CUTS INTERNATIONAL – RAMAN DEVELOPMENT CONSULTANTS PVT. LTD. PRESENTATION ON KEY FINDINGS: BRCC PROJECT- GUJARAT 11th September, 2012

  3. Presentation Points • A brief introduction to the project • A brief introduction to the Approach & methodology • Key Stakeholders • Findings of Pharma Sector – Environment Related Inquiry • Findings of Pharma Sector – Marketing & Distribution Related Inquiry • Findings of Private health care sector – Environment Related Inquiry • Findings of Private health care Sector – Marketing & Distribution Related Inquiry RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  4. BRCC Project Overview Business Regulation and Corporate Conduct - BRCC Implementers: • Consumer Unity & Trust Society (CUTS International) • Norwegian Institute of International Affairs (NUPI) • Raman Development Consultants Pvt. Ltd. (RDC) – Gujarat State Partner Duration:April 2011 to December 2012

  5. BRCC Project • Sectoral Focus : • Pharmaceutical Sector • Private Healthcare Sector • Geographical Focus : • Andhra Pradesh • Gujarat • Himachal Pradesh • West Bengal

  6. Policy & Regulatory Framework Business Development Optimal Practical Facilitating Responsible Ethical Society friendly Environment friendly Inclusive Sustainable

  7. Business Regulation & Corporate Conduct Mandatory Regulation Guiding Benchmarks Government Conduct Society Environment

  8. Objectives of the Project • Address the regulatory and operational constraints faced by businesses in India. • Motivate firms to adopt ‘Responsible Corporate Conduct’. • Evolve a policy discourse between business community and policymakers to facilitate a policy environment that promotes business development in a sustainable manner. Thrust:Encouraging responsible corporate conduct and building optimal regulatory framework through focused, informed and continuous discourse among government, business and stakeholders

  9. Key Areas of Inquiry • Current Situation and gaps • Why have the regulatory safeguards not effective in addressing the gaps? • What should be done to make the regulatory safe guards work? • What role is expected from the industry collectives? RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  10. Critical Issues in Pharmaceutical Sector • Environment Problem : • Current level of adverse environmental Impact • Why have the regulatory safeguards not worked where there are significant impacts ? • What should be done to make these regulation work, so that such adverse impacts can be minimized? • Marketing & Distribution Problem : • Current status of incentives provided by companies to doctors and chemist • Its impact on ‘Rational Use of Drugs’ • Why have these incentives continued despite regulations? • What can be done to ensure companies undertake their marketing supporting rational use of drugs? • Presence of expired drugs in the market? Reasons of presence in spite of regulations • What should be done to make betterment in the drug supply chain?

  11. Critical Issues in Private Healthcare Sector • Environment Problem : • Current status of bio-medical waste management practices by hospitals and diagostic service providers • If situation is problematic, explore why it is so despite regulations • How the situation can be corrected • Steps taken by hospital associations/industry bodies • What are the good practices? Drivers of good practices • Marketing & Distribution Problem: • Prevalence of ‘cuts/commission to doctors by diagnostic service providers • Why ‘cut/commissions’ exist in spite of regulatory safeguards? • How the situation can be corrected • Steps taken by hospital associations/other associations • What are the regulatory barriers? • Extent to which Standard Treatment Protocol are followed • Reasons for deviation and other non compliances • How it can be ensured hospitals promote alignment with Standard Treatment Protocols • Adequate measures by HCPs to respect and address diagnosis & treatment related queries of clients? • Any other self regulatory mechanisms in place?

  12. Stakeholders for Pharma Sector • Government Department • Health and Family Welfare Department • Gujarat Pollution Control Board • Food and Drug Control Administration • Commissioner of Industries • Associations of Pharmaceutical Industry including Small, Medium and Large Scale Manufacturers (Formulation and Bulk drug Industries) & Other related stakeholders • IDMA • Indian Pharmaceutical Association • Pharma Export Council • Ahmedabad Chemist Association • Gujarat State Medical Representatives Association

  13. Stakeholders for Pharma Sector • Industrial Associations • Gujarat Chamber of Commerce and Industry • Associated Chambers of Commerce and Industry of India (ACCII) • FICCI • ASSOCHAM • Local GIDC Associations • District Level Industrial Associations • Academic Institutions • Individual Pharmaceutical Firms • Civil Society Organizations • Media • Community residing in proximity of Pharma Units

  14. Stakeholders for Private Healthcare Sector • Government Department • Health and Family Welfare Department • Gujarat Pollution Control Board • Medical Associations • Gujarat Medical Council • Indian Medical Association • Ahmedabad Medical Association • Private Hospitals • Biomedical waste management units • Academic Institutions • Civil Society Organization • Media • Consumers availing services of private hospitals

  15. Approach and Methodology RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  16. Status of Field Work RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  17. Findings of Pharma Sector – Environment Related Inquiry RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  18. Findings of Phase I: Pharma Firms • Good Manufacturing Process (GMP) • 93.33 % firms are aware, 83.08 % respondents all elements of GMP as below: • Disposal of sewage & wastes in conformity with requirement of SPCB, • Standard operating procedures for sampling, Inspecting and testing of raw materials, • Verification of environmental procedures, • Filling products in powder form exercised with special care so as to avoid contamination of environment • Filter installed to retain dust and protect the local environment RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  19. Difficulties and Expectations of Pharma firms to follow GMP RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  20. Contribution of the Pharma industry to the environmental impacts • 33.33 firms discuss it in board room meeting • 86.48 % ensure compliance to env. Practice even in outsourcing through contract or encouragement RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  21. Contribution of the Pharma industry to the environmental impacts • 82.86% respondents expects different regulatory laws and implementation according to nature of the unit and size of firms • 65.33 % firms does not have dedicated Environment Management Department • 98.48 % did not receive any assistance from government RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  22. Social responsibility of Pharma firms • 81.43 % firms covered under survey does not have CSR policy • Out of the firms which reported doing some CSR activities, half of them reported doing it out of individual philanthropic sentiments • 91.78 % reported being Unaware of NVGs RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  23. Pharma Associations.. • India Drug Manufacture’s Association (IDMA) • Large and medium firms highly adhere regulatory compliance of the different segments of the pharma sector in the state while small firms adhere at medium level. • Lack of awareness among firms/ association and financial constraints reported as among major difficulties to adhere regulatory requirements of GMP by firms • Government should consider providing financial support and should keep firms interest also in mind while formulating such regulations • IDMA does interact with government and other stakeholders on different issues of pharma RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  24. Findings of Pharma Sector – Marketing & Distribution Related Inquiry RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  25. Marketing & Distribution • Use of Medical Representatives was reported as a major strategy for M&D by 73.24 % firms • 68.42 firms reported awareness on Code of Medical Ethics Regulations, 2002 • 57.50% of firms reportedawareness on Uniform Code for Pharmaceutical Marketing Practices RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  26. Marketing & Distribution • 41.18 % firms reported sponsoring events for doctors • 77.42 % of firms reported that Doctors ask MRs for gifts during their visits • 68.57% firms reported considering it as bad conduct to ask for gifts • 40% firms reported indulging into distribution of gifts/incentives in order to maximize profit and gain new markets, while 24.44 % think that it is ‘essential to survive’ RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  27. Findings from MR study • 80% of MR reported that that meeting with the doctors is primarily a part of marketing strategy • Based on the responses, the value addition through the meetings by MRs can be classified as follows: • Information related to new drugs in market (60%) • Information on latest development in pharma industry (37.14%) • Building good relationship between Doctors and pharmaceutical firms (48.17%) RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  28. Findings from MR study • 85.7% MRs reported being asked by Doctors for any kind of gifts/incentives during their visit • Reporting about the motive of asking for gifts/incentives, major reasons reported were: • To promote product (54.28%) • Giving time to MR to meet (28.51%). • 40% MRs reported that it is a regular practice to give gifts to doctors, while 60 % reported that gifts are distributed only on special occasions • 54.28 % MRs reportedawareness about UCPMP RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  29. Findings from Pharma Association.. • India Drug Manufacture’s Association (IDMA) & & Associated Chambers of Commerce and Industry of India (ACCII) • Both association do not have specific mechanism to monitor marketing strategy of member firms. • Both are aware of Code of Medical Ethics Regulations, 2002 and also were in favor of it • Both association are unaware of Uniform Code for Pharmaceutical Marketing Practices. RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  30. Findings from PharmaAssociation.. Ahmedabad Chemist Association • Incentive regime – reasons are commercial motivation of doctors and weak regulatory framework • Increasing number of companies and number of products is the main challenge faced by ACA • MR's working with different pharmaceutical firms often create pressure on chemists to increase sale of their products • Chemists often sell over the counter (OTC) drugs without prescription • Prescriptions often contain expensive medicines in spite of the availability of cheaper generic version • Aware about Medical Ethics Regulations, (Professional conduct, Etiquette and Ethics) 2002 formulated by Medical Council of India (MCI) and The Uniform Code of Pharmaceuticals Marketing Practices RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  31. Findings from PharmaAssociation.. Medical Representative Association • Gifts are distributed on regular basis not on only some special occasion. Such gifts are booked by pharma firm under “Gratification” head • Aware about Medical Ethics Regulations & The Uniform Code of Pharmaceuticals Marketing Practices • Incentive regime” in pharma industry is contributed mainly by business strategy of pharma industry, commercial motivation of doctors, and weak regulatory framework • Fix remuneration would be more stable option for MRs • Regulatory set-up is not sufficient and optimal enough to ensure responsible and ethical corporate conduct on the part of Pharmaceutical Firms • GSMRA never had interaction with any other body RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  32. Findings of Private Health care sector – Environment Related Inquiry RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  33. Private Hospital study results • Coverage of private hospitals under study • 69.33 % of private hospitals reported following some guidelines/code of conduct for providing optimal healthcare service to the patients • 79.73% reported maintaining patient satisfaction record and want it be mandatory. Same % of respondents mentioned it to be mandatory. RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  34. Private Hospital study results • In term of interactions with SPCB, 53.52% found it as “OK, the way it is”, while 32.39 felt there is a “need for improvement” • In terms of interactions with state health administration and 40.91 % find it as “OK, the way it is” while 33% reported that there is a “need for improvement” • 80.82% private hospitals reported that they are not part of any association of hospitals RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  35. Private Hospital study results: BMW • 98.65 % private hospitals are aware of BMW rule 1998 • Various mode through which the Hospitals manage BMW were found reported as follows: • Through private BMW service provider – 78.21 % • Though common BMW treatment facility – 17.95 % • Stand alone facility in hospital- 1.28 % • 33.33% reported that there is a need for improvement in BMW rules RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  36. Private Hospital study results: BMW • Almost all (>99%) the hospitals reported that their staff has undergone the training on BMW. About half of these (50%) reported undergoing process oriented training • 82.43% private hospitals reported having some specific mechanism in place to carry out quality assessment of BMW • 71.62% hospitals reported submitting periodic reports on BMW management, mainly to SPCB RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  37. Private Hospital: BMW: Difficulties & Expectations RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  38. Private Hospital study results • 65.75 % hospitals reported having a CSR policy in place • 89.04% private hospitals reported providing free of cost/concessional treatment to BPL or poor patients • 83.10 % hospitals reported no awareness about NVGs RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  39. Findings from Private Health care Association • Associated Chambers of Commerce and Industry of India (ACCII): • Challenges relating to the Private Healthcare and Pharmaceutical Sectorwere reported as mainly - • Nexus between private health care and pharma sector, • Increasing cases related to unethical practices from the part of private health care system • Profit oriented approach of private health care sector • Lack of regulatory framework to ensure responsible conduct from private health care sector • Aware about NVG and BMW rules • For Long term solution of BMW issues Consistent and better informed government regulations, strict enforcement of regulations and self regulations are key strategies RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  40. Findings from BMW Service Providers • Large hospitals perform “fair” for BMW management while medium and small hospitals perform “poor’ • Less willingness of hospitals to manage BMW • Waste received from hospitals are segregated properly • SPCB performance was described as ‘good’ RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  41. Findings of Private Health Care Sector – Marketing & Distribution Related Inquiry RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  42. Private Hospital study results: • 75. 68 % hospitals reported no awareness about UCPMP • 77.03 % reported being aware of Medical Ethics Regulations, 2002 • 45.71 % hospitals reported having mechanisms in place to ascertain their in-house and/or empanelled doctors follow such guidelines • 64.38 % hospitals are in favor of support mandatory prescription audit while 32.88 % are not in favor of it. • 83.78 % hospitals reported not having any specific instrument to guide doctors on medicine prescriptions and allowed doctors to prescribe medicine at their discretion RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  43. Private Hospital study results: • 60.27 % private hospitals does not have any in-house guideline on Rational Use of Drugs in the hospitals • 49.32% hospitals favored mandatory STP for private hospitals while 50.68% did not favor it • 75% hospitals reported existence of a nexus between hospitals and pharma industry, necessary for two interdependent business entities. • On questioning hospitals about what they consider as determinants of unethical behavior in private healthcare in state, following major responses were reported: • 25.23 % - weak regulatory framework • 23.42 % - incentives by pharma firms • 22.52 % - commercial motivation of doctors RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  44. Private Healthcare Association.. Ahmedabad Medical Association: • The AMA does neither have any state/locality-specific regulatory instruments (code/manual/guidelines etc.) put in place for the private healthcare providers/doctors to follow nor does they have any monitoring mechanisms to ascertain its compliance • Unaware of NVG and UCPMP, aware of Medical Ethics Regulations, 2002 • Lack of communication between government and private hospitals is the key issue faced by Private health sector • AMA does not developed any specific instrument (policy/code/manual/guideline etc.) for its member doctors on medicine prescriptions nor on rational use of drugs • STP should be mandatory for doctors/ private hospitals • State health/local health administration should do prescription audit, and private healthcare sector should disease registry RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  45. Findings from Prescription Analysis • Coverage: 145 prescriptions from different hospitals in Ahmedabad • In Subscription part: • Gender and age of patient were mentioned in 13.8% prescriptions • Address of the patient was not mentioned in any the prescription • T for tablet and Inj for injection mentioned in all • Dose of drug was not completely written in 75.8% of prescription • Duration of treatment were not mentioned in 84.13% of prescription • Direction of use of drug was not properly mentioned in 77.24%case • In all 81.37% prescription were illegible RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  46. Findings from Prescription Analysis • In 37.24 % prescriptions 1-2 drugs were prescribed • In 42.07 % prescriptions 3-4 drugs were prescribed • In 20.69 % prescriptions 5 or >5 drugs were prescribed RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  47. Findings from Prescription Analysis RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  48. EmergingMessages • Stricter monitoring and effective implementation of rules and regulation by regulators • More, systematic and mandatory efforts for Capacity building of all stakeholders and leadership by state • Systematic efforts to promote increased self regulation with associated sizeable incentives • Industry collectives to take up a more proactive role in effective implementation of regulations • Increased inter-sectoral dialogues for environmental issues due to pharma and private health care firms • Mechanism to curb unethical practices in the sector • Combination of negative and positive incentives for firms for compliances to rules and regulations RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  49. Thank You RDC/ CUTS/ BRCC-Gujarat : 11-9-2012

  50. Status of Field Work

More Related